Literature DB >> 7428142

Recruitment of patients to cooperative group clinical trials.

J Y Lee, J E Marks, J R Simpson.   

Abstract

One of the prerequisites for a successful clinical trial is the accrual of a sufficient number of patients for study. Because the sample-size requirements for a randomized clinical trial can rarely be met by a single institution in a short period of time, cooperative groups have taken in a major role in conducting clinical trials. In this paper, the recruitment of patients at our institution to a lung cancer clinical trial is evaluated. A total of 653 lung cancer cases were reviewed. Of the 77 cases which were eligible for the trial, 41 were accessioned. The reasons why eligible patients were not accessioned to the trial are discussed.

Entities:  

Mesh:

Year:  1980        PMID: 7428142

Source DB:  PubMed          Journal:  Cancer Clin Trials        ISSN: 0190-1206


  5 in total

1.  Designing clinical protocols for optimal use: measuring attributes of treatment and cancer control trials.

Authors:  J E Veney; W P Kory; J M Barnsley; A D Kaluzny
Journal:  J Med Syst       Date:  1991-12       Impact factor: 4.460

2.  Attitude of African-Americans regarding prostate cancer clinical trials.

Authors:  S B Robinson; M Ashley; M A Haynes
Journal:  J Community Health       Date:  1996-04

3.  Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews.

Authors:  Edgardo Rodríguez-Torres; Margarita M González-Pérez; Clemente Díaz-Pérez
Journal:  Contemp Clin Trials Commun       Date:  2021-08-03

4.  Competing commitments in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Steven Joffe; Karen Albert; Jill Rosenbaum; Lorna Simon
Journal:  IRB       Date:  2009 Sep-Oct

Review 5.  Are racial and ethnic minorities less willing to participate in health research?

Authors:  David Wendler; Raynard Kington; Jennifer Madans; Gretchen Van Wye; Heidi Christ-Schmidt; Laura A Pratt; Otis W Brawley; Cary P Gross; Ezekiel Emanuel
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.